WO2022189599A1 - Crystalline forms of mavacamten for the treatment of hcm - Google Patents
Crystalline forms of mavacamten for the treatment of hcm Download PDFInfo
- Publication number
- WO2022189599A1 WO2022189599A1 PCT/EP2022/056267 EP2022056267W WO2022189599A1 WO 2022189599 A1 WO2022189599 A1 WO 2022189599A1 EP 2022056267 W EP2022056267 W EP 2022056267W WO 2022189599 A1 WO2022189599 A1 WO 2022189599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mavacamten
- crystalline form
- range
- theta
- present
- Prior art date
Links
- RLCLASQCAPXVLM-NSHDSACASA-N CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O Chemical compound CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O RLCLASQCAPXVLM-NSHDSACASA-N 0.000 title claims abstract description 136
- 229940069673 mavacamten Drugs 0.000 title claims abstract description 108
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims abstract description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000005855 radiation Effects 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008184 oral solid dosage form Substances 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 10
- 238000000634 powder X-ray diffraction Methods 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 238000000113 differential scanning calorimetry Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 10
- -1 for example Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000020446 Cardiac disease Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Chemical class 0.000 description 1
- 229940122960 Myosin inhibitor Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000003991 Rietveld refinement Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical group [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940093932 potassium hydroxide Drugs 0.000 description 1
- 229920003124 powdered cellulose Chemical class 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to anhydrous crystalline forms of mavacamten and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising an anhydrous crystalline form of the present invention and at least one pharmaceutically acceptable excipient.
- the pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypertrophic cardiomyopathy (HCM).
- HCM hypertrophic cardiomyopathy
- Mavacamten is an oral cardiac myosin inhibitor investigated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), non-obstructive HCM and precision diastolic disease.
- HCM hypertrophic cardiomyopathy
- the chemical name of macacamten is fV)-3-isopropyl-6-((l - phenylethyl)amino)pyrimidine-2,4( l//,3//)-dione.
- Mavacamten can be represented by the following chemical structure according to Formula (A)
- mavacamten and its preparation are disclosed in WO 2014/205223 Al.
- mavacamten is obtained as white solid after precipitation from ethyl acetate and further stirring in a solvent mixture of ethyl acetate/ «-hexane.
- the same process is disclosed in example 1 of WO 2019/028360 Al. Both documents are silent about the nature of the solid-state form obtained though.
- Different solid-state forms of an active pharmaceutical ingredient often possess different properties. Differences in physicochemical properties of solid-state forms can play a crucial role for the improvement of pharmaceutical compositions, for example, pharmaceutical formulations with improved dissolution profile and bioavailability or with improved stability or shelf-life can become accessible due to an improved solid-state form of an active pharmaceutical ingredient. Also processing or handling of the active pharmaceutical ingredient during the formulation process may be improved. New solid-state forms of an active pharmaceutical ingredient can thus have desirable processing properties. They can be easier to handle, better suited for storage, and/or allow for better purification, compared to previously known solid-state forms.
- the sudden appearance or disappearance of a metastable polymorph can present a problem in pharmaceutical development.
- serious pharmaceutical consequences may arise if transformation occurs in a dosage form, e.g. upon storage.
- the present invention provides anhydrous crystalline forms of mavacamten, hereinafter also designated as “Form I”, “Form II”, “Form III”, “Form IV”, “Form V” and “Form VI”.
- the crystalline forms of the present invention possess one or more advantageous properties selected from the group consisting of chemical stability, physical stability, melting point, hygroscopicity, solubility, dissolution, morphology, crystallinity, flowability, bulk density, compactibility and wettability.
- the crystalline forms of the present invention are stable against temperature stress e.g. they don’t show any thermal events during DSC up to a temperature of about 170°C.
- mavacamten Form I of the present invention was found to be the most stable form at room temperature.
- the usage of a stable API form is of great importance since polymorphic conversions, which may occur during the manufacturing process and/or during storage of a drug substance or drug product containing the drug substance can be excluded when a stable form is used. This ensures reliable bioavailability and therefore consistent efficacy and safety of the drug product containing the stable form throughout shelf-life.
- the term “measured at a temperature in the range of from 20 to 30°C” refers to a measurement under standard conditions.
- standard conditions mean a temperature in the range of from 20 to 30°C, i.e. at room temperature.
- Standard conditions can mean a temperature of about 22°C.
- standard conditions can additionally mean a measurement at 20-60% RH, preferably at 30-50% RH, more preferably at 40% RH.
- room temperature refers to a temperature in the range of from 20 to 30°C.
- reflection with regard to powder X-ray diffraction as used herein, means peaks in an X-ray diffractogram, which are caused at certain diffraction angles (Bragg angles) by constructive interference from X-rays scattered by parallel planes of atoms in solid material, which are distributed in an ordered and repetitive pattern in a long-range positional order.
- a solid material is classified as crystalline material, whereas amorphous material is defined as solid material, which lacks long-range order and only displays short-range order, thus resulting in broad scattering.
- long-range order e.g.
- the term “essentially the same” with reference to powder X-ray diffraction means that variabilities in reflection positions and relative intensities of the reflections are to be taken into account.
- a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- a reflection that usually appears at 10.1° 2-Theta for example can appear between 10.0° and 10.2° 2-Theta on most X-ray diffractometers under standard conditions.
- relative reflection intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, particle size, sample preparation and other factors known to those skilled in the art and should be taken as qualitative measure only.
- a crystalline form of mavacamten of the present invention may be referred to herein as being characterized by graphical data "as shown in" a figure.
- Such data include, for example, powder X-ray diffraction.
- factors such as variations in instrument type, response and variations in sample directionality, sample concentration and sample purity may lead to small variations for such data when presented in graphical form, for example variations relating to the exact reflection positions and intensities.
- a comparison of the graphical data in the figures herein with the graphical data generated for another or an unknown solid form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
- solid-state form refers to any crystalline and/or amorphous phase of a compound.
- amorphous refers to a solid-state form of a compound that is not crystalline. An amorphous compound possesses no long-range order and does not display a definitive X-ray diffraction pattern with reflections.
- anhydrous form or “anhydrate” as used herein refer to a crystalline solid where no water is cooperated in or accommodated by the crystal structure.
- Anhydrous forms may still contain residual water, which is not part of the crystal structure but may be adsorbed on the surface or absorbed in disordered regions of the crystal.
- non-solvated as used herein, when talking about a crystalline solid indicates that no organic solvent is cooperated in or accommodated by the crystal structure.
- Non-solvated forms may still contain residual organic solvents, which are not part of the crystal structure but may be adsorbed on the surface or absorbed in disordered regions of the crystal.
- a “predetermined amount” as used herein with regard to a crystalline form of mavacamten refers to the initial amount of the crystalline form used for the preparation of a pharmaceutical composition having a desired dosage strength of mavacamten.
- the term “about” means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, typically within 10%, more typically within 5%, even more typically within 1% and most typically within 0.1% of the indicated value or range. Sometimes, such a range can lie within the experimental error, typical of standard methods used for the measurement and/or determination of a given value or range.
- pharmaceutically acceptable excipient refers to substances, which do not show a significant pharmacological activity at the given dose and that are added to a pharmaceutical composition in addition to the active pharmaceutical ingredient. Excipients may take the function of vehicle, diluent, release agent, disintegrating agent, dissolution modifying agent, absorption enhancer, stabilizer or a manufacturing aid among others. Excipients may include fillers (diluents), binders, disintegrants, lubricants and glidants.
- filler or “diluent” as used herein refer to substances that are used to dilute the active pharmaceutical ingredient prior to delivery. Diluents and fillers can also serve as stabilizers.
- binder refers to substances which bind the active pharmaceutical ingredient and pharmaceutically acceptable excipient together to maintain cohesive and discrete portions.
- disintegrant or “disintegrating agent” as used herein refers to substances which, upon addition to a solid pharmaceutical composition, facilitate its break-up or disintegration after administration and permits the release of the active pharmaceutical ingredient as efficiently as possible to allow for its rapid dissolution.
- lubricant refers to substances which are added to a powder blend to prevent the compacted powder mass from sticking to the equipment during tableting or encapsulation process. They aid the ejection of the tablet from the dies and can improve powder flow.
- glidant refers to substances which are used for tablet and capsule formulations in order to improve flow properties during tablet compression and to produce an anti -caking effect.
- Figure 1 illustrates a representative PXRD of mavacamten Form I according to the present invention.
- the x-axis shows the scattering angle in °2-Theta
- the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
- Figure 2 illustrates a representative PXRD of mavacamten Form II according to the present invention.
- the x-axis shows the scattering angle in °2-Theta
- the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
- Figure 3 illustrates a representative PXRD of mavacamten Form III according to the present invention.
- the x-axis shows the scattering angle in °2-Theta
- the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
- Figure 4 illustrates a representative PXRD of mavacamten Form IV according to the present invention.
- the x-axis shows the scattering angle in °2-Theta
- the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
- Figure 5 illustrates a representative PXRD of mavacamten Form V according to the present invention.
- the x-axis shows the scattering angle in °2-Theta
- the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
- Figure 6 illustrates a comparison of PXRDs of mavacamten Form I, Form II, Form III, Form IV and Form V (from top to bottom).
- the x-axis shows the scattering angle in °2-Theta.
- the PXRDs were shifted along the y-axis to separate the diffractograms for clarity.
- Figure 7 illustrates a representative DSC curve of mavacamten Form I according to the present invention.
- the x-axis shows the temperature in degree Celsius (°C)
- the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
- Figure 8 illustrates a representative DSC curve of mavacamten Form II according to the present invention.
- the x-axis shows the temperature in degree Celsius (°C)
- the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
- Figure 9 illustrates a representative DSC curve of mavacamten Form III according to the present invention.
- the x-axis shows the temperature in degree Celsius (°C)
- the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
- Figure 10 illustrates a representative DSC curve of mavacamten Form IV according to the present invention.
- the x-axis shows the temperature in degree Celsius (°C)
- the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
- Figure 11 illustrates a representative DSC curve of mavacamten Form V according to the present invention.
- the x-axis shows the temperature in degree Celsius (°C)
- the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
- the present invention relates to a crystalline form of mavacamten according to the chemical structure as depicted in Formula (A)
- Formula (A) characterized in being anhydrous.
- the invention provides anhydrous crystalline forms of mavacamten, hereinafter also designated as “Form I”, “Form II”, “Form III”, “Form IV”, “Form V” and “Form VI”.
- the crystalline forms of mavacamten of the present invention may be characterized by analytical methods well known in the field of the pharmaceutical industry for characterizing solids. Such methods comprise but are not limited to powder X-ray diffraction, single X-ray diffraction, FTIR spectroscopy, DSC, TGA and GMS.
- the crystalline forms of the present invention may be characterized by one of the aforementioned analytical methods or by combining two or more of them.
- the crystalline forms of mavacamten of the present invention may be characterized by any one of the following embodiments or by combining two or more of the following embodiments.
- the invention relates to a crystalline form (Form I) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
- the invention relates to a crystalline form of mavacamten (Form I) as defined in any one of the above described embodiments characterized by having a PXRD comprising no reflections at or below (9.8 ⁇ 0.1)° 2-Theta, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
- the present invention relates to a crystalline form of mavacamten (Form I) characterized by having a PXRD essentially the same as shown in Figure 1 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
- the present invention relates to a crystalline form of mavacamten (Form I) characterized by exhibiting an orthorhombic unit cell having space group 2i2i2i.
- the present invention relates to a crystalline form (Form I) of mavacamten, characterized by having a melting point onset at a temperature of about 224.5°C, when measured with DSC at a heating rate of 10 K/min.
- the present invention relates to a crystalline form (Form I) of mavacamten characterized in being anhydrous.
- the present invention relates to a crystalline form (Form I) of mavacamten characterized in being non-solvated.
- the invention relates to a crystalline form (Form II) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
- the present invention relates to a crystalline form of mavacamten (Form II) characterized by having a PXRD essentially the same as shown in Figure 2 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
- the present invention relates to a crystalline form of mavacamten
- the present invention relates to a crystalline form (Form II) of mavacamten, characterized by having a melting point onset at a temperature of about 238°C, when measured with DSC at a heating rate of 10 K/min.
- the present invention relates to a crystalline form (Form II) of mavacamten characterized in being anhydrous.
- the present invention relates to a crystalline form (Form II) of mavacamten characterized in being non-solvated.
- the invention relates to a crystalline form (Form III) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
- the present invention relates to a crystalline form of mavacamten (Form III) characterized by having a PXRD essentially the same as shown in Figure 3 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
- the present invention relates to a crystalline form of mavacamten
- Form III characterized by exhibiting a monoclinic unit cell having space group 12
- the present invention relates to a crystalline form (Form III) of mavacamten, characterized by having a melting point onset at a temperature of about 249.5°C, when measured with DSC at a heating rate of 10 K/min.
- the present invention relates to a crystalline form (Form III) of mavacamten characterized in being anhydrous.
- the present invention relates to a crystalline form (Form III) of mavacamten characterized in being non-solvated.
- the invention relates to a crystalline form (Form IV) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
- the present invention relates to a crystalline form of mavacamten (Form IV) characterized by having a PXRD essentially the same as shown in Figure 4 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
- the present invention relates to a crystalline form of mavacamten
- the present invention relates to a crystalline form (Form IV) of mavacamten, characterized by having a melting point onset at a temperature of about 236°C, when measured with DSC at a heating rate of 10 K/min.
- the present invention relates to a crystalline form (Form IV) of mavacamten characterized in being anhydrous.
- the present invention relates to a crystalline form (Form IV) of mavacamten characterized in being non-solvated.
- the invention relates to a crystalline form (Form V) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
- the present invention relates to a crystalline form of mavacamten (Form V) characterized by having a PXRD essentially the same as shown in Figure 5 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
- the present invention relates to a crystalline form of mavacamten (Form V) characterized by exhibiting an orthorhombic unit cell having space group 2i2i2.
- the present invention relates to a crystalline form (Form V) of mavacamten, characterized by having a melting point onset at a temperature of about 240°C, when measured with DSC at a heating rate of 10 K/min.
- the present invention relates to a crystalline form (Form V) of mavacamten characterized in being anhydrous.
- the present invention relates to a crystalline form (Form V) of mavacamten characterized in being non-solvated.
- the invention relates to a crystalline form (Form VI) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
- the present invention relates to a crystalline form (Form VI) of mavacamten characterized in being anhydrous.
- the present invention relates to a crystalline form (Form VI) of mavacamten characterized in being non-solvated.
- the present invention relates to the use of crystalline mavacamten (e.g . Form
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) of the present invention as defined in any one of the above described aspects and their corresponding embodiments, preferably in an effective and/or predetermined amount, and at least one pharmaceutically acceptable excipient.
- crystalline mavacamten e.g. Form I, II, III, IV, V or VI as defined herein
- the effective and/or predetermined amount of crystalline mavacamten e.g. Form I,
- the effective and/or predetermined amount is selected from the group consisting of 1 mg, 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg and 50 mg calculated as mavacamten (water free).
- the effective and/or predetermined amount is selected from the group consisting of 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg calculated as mavacamten (water free).
- the at least one pharmaceutically acceptable excipient, which is comprised in the pharmaceutical composition of the present invention is preferably selected from the group consisting of fillers, disintegrants, binders, lubricants, glidants and combinations thereof.
- the at least one pharmaceutically acceptable excipient, which is comprised in the pharmaceutical composition of the present invention is selected from the group consisting of fillers, glidants and combinations thereof.
- the filler is selected from the group consisting of dibasic calcium phosphate, kaolin, lactose, dextrose, magnesium carbonate, sucrose, mannitol, glucose or other monosaccharides, dextrin or other polysaccharides, microcrystalline cellulose, powdered cellulose, cellulose derivatives, precipitated calcium carbonate, calcium sulfate, sorbitol, inositol and starch, and combinations thereof.
- the glidant is selected from the group consisting of coloidal silica, colloidal silicon dioxide, fumed silica, silicon dioxide, com starch, talc, calcium silicate, magnesium silicate, tribasic calcium phosphate, silicon hydrogel, and combinations thereof.
- the pharmaceutical composition of the present invention as defined in any one of the above described embodiments is an oral solid dosage form, more preferably a tablet or a capsule.
- the pharmaceutical composition of the present invention as described above is a capsule, preferably a hard gelatin capsule.
- compositions of the present invention as defined in any one of the above described embodiments may be produced by standard manufacturing processes, which are well- known to the skilled person e.g. selected from the group consisting of micronization, blending, milling, granulation (wet or dry granulation), capsule filling, tabletting, film-coating and any combinations thereof.
- the present invention relates to crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) or a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments for use as a medicament.
- crystalline mavacamten e.g. Form I, II, III, IV, V or VI as defined herein
- a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments for use as a medicament.
- the present invention relates to crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) or a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments for use in the treatment of cardiac disorder.
- crystalline mavacamten e.g. Form I, II, III, IV, V or VI as defined herein
- a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments for use in the treatment of cardiac disorder.
- the present invention relates to a method of treating a cardiac disorder said method comprising administering an effective amount of crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) or a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments to a patient in need of such a treatment.
- the cardiac disorder is selected from the group consisting of hypertrophic cardiomyopathy (HCM), such as obstructive HCM and non-obstructive HCM, and precision diastolic disease.
- HCM hypertrophic cardiomyopathy
- the cardiac disorder is ostructive HCM.
- the invention in another aspect relates to crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) for use in the preparation of a pharmaceutically acceptable salt of mavacamten.
- crystalline mavacamten e.g. Form I, II, III, IV, V or VI as defined herein
- the pharmaceutically acceptable salt is an acid addition salt or a base addition salt, preferably an acid addition salt.
- Pharmaceutically acceptable salts may be derived by reacting crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) with an acid or a base in a suitable solvent or solvent mixture.
- the acid may be selected from the group consisting of acetic acid, adipic acid, alginic acid, aminosalicylic acid, /.-ascorpic acid, L- aspartic acid, aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphor-10-sulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, galactaric acid, //-glucaric acid, //-gluconic acid, //-glucuronic acid, /.-gluta ic acid, glutaric acid, hippuric acid, hydrochloric acid, hydrobromic acid, lactic acid, lactobionic acid, lauric acid, malic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, naphtalene-l,5-disulfonic acid, naphtelene-2- sulfonic acid, nitric acid, oxalic acid, pamoic acid, phospho
- the base may be selected from the group consisting of aluminum, ammonia, /.-arginine, benethamine, benzathine, tert- butylamine, calcium hydroxide, chloroprocaine, choline hydroxide, diethanolamine, diethylamine, ethanolamine, ethylenediamine, lithium, /.-lysine, magnesium hydroxide, meglumine, piperazine, potassium hydroxide, procaine, sodium hydroxide, tromethamine and zinc hydroxide.
- the mavacamten starting material was obtained by following the procedure disclosed in example 1 of WO 2014/205223 Al.
- Example 1 Preparation of mavacamten Form I
- Mavacamten (45 mg) was dissolved in ethanol (1.8 mL) upon heating. The resulting clear solution was filtrated and allowed to naturally cool to room temperature, whereat crystals formed within 24 hours. Subsequently, the mixture was cooled to -20°C for about 16 hours before the crystals were collected by filtration and air-dried to obtain crystalline Form I of mavacamten.
- Mavacamten (Form I, Form II, Form IV or Form V prepared according to the procedures disclosed herein) was annealed at 240°C for 5 minutes and at 210°C for 10 minutes. The sample was then cooled to room temperature to obtain crystalline Form III of mavacamten.
- Mavacamten (130 mg) was dissolved in isopropanol (20 mL) upon heating to reflux temperature. The resulting clear solution was filtrated and the solvent removed on a rotavapor (40°C, 50-100 mbar) under reduced pressure to obtain crystalline Form IV of mavacamten.
- the powder X-ray diffraction patterns were recorded (at 25°C) with a X’Pert PRO diffractometer (PANalytical, Almelo, The Netherlands), equipped with a Theta/Theta coupled goniometer in transmission geometry, programmable XYZ stage with well plate holder, Cu- Kalphai,2 radiation source with a focussing mirror, a 0.5° divergence slit, a 0.02° sober slit collimator and a 1° anti -scattering slit on the incident beam side, a 2 mm anti -scattering slit, a 0.04° sober slit collimator, a Ni-filter, and a solid state PIXcel detector on the diffracted beam side.
- the patterns were recorded at a tube voltage of 40 kV, tube current of 40 mA, applying a step-size of 0.007° 2-Theta with 400 s per step in the angular range of 2° to 70
- a representative diffractogram of mavacamten Form I is displayed in Figure 1 hereinafter.
- the corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 1 below.
- Table 1 Reflection positions of crystalline Form I of mavacamten in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- a representative diffractogram of mavacamten Form II is displayed in Figure 2 hereinafter.
- the corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 2 below.
- Table 2 Reflection positions of crystalline Form II of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- a representative diffractogram of mavacamten Form III is displayed in Figure 3 hereinafter.
- the corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 3 below.
- Table 3 Reflection positions of crystalline Form III of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- a representative diffractogram of mavacamten Form IV is displayed in Figure 4 hereinafter.
- the corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 4 below.
- Table 4 Reflection positions of crystalline Form IV of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- a representative diffractogram of mavacamten Form V is displayed in Figure 5 hereinafter. The corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 5 below.
- Table 5 Reflection positions of crystalline Form V of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- the reflection list of mavacamten Form VI in the range of from 2 to 30° 2-Theta is provided in
- the reflection list of mavacamten pyridine hemi solvate in the range of from 2 to 30° 2-Theta is provided in Table 7 below.
- Table 7 Reflection positions of crystalline mavacamten pyridine hera/solvate in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- Table 8 Reflection positions of crystalline mavacamten chloroform monosolvate in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ⁇ 0.1° 2-Theta.
- the reflection list of mavacamten NMP hemi solvate in the range of from 2 to 30° 2-Theta is provided in Table 9 below.
- Mavacamten Forms I to V were indexed and the space groups were determined based on a statistical assessment of systematic absences using DicvoKM 1 as implemented in HighScore Plus 3.0.5 (PANalytical, Almelo, The Netherlands). Pawley fits and Rietveld refinements were performed with Topas v.4.1 (Bruker AXS Inc., Madison, Wisconsin, USA).
- Table 10 Crystallographic information for mavacamten forms I to V
- Example 12 Differential Scanning Calorimetry
- DSC Differential Scanning Calorimetry
Abstract
The present invention relates to anhydrous crystalline forms of mavacamten and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising an anhydrous crystalline form of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypertrophic cardiomyopathy (HCM).
Description
WO 2022/189599 _ j _ PCT/EP2022/056267
CRYSTALLINE FORMS OF MAVACAMTEN FOR THE TREATMENT OF HCM
FIELD OF THE INVENTION
The present invention relates to anhydrous crystalline forms of mavacamten and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising an anhydrous crystalline form of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypertrophic cardiomyopathy (HCM).
BACKGROUND OF THE INVENTION Mavacamten is an oral cardiac myosin inhibitor investigated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), non-obstructive HCM and precision diastolic disease. The chemical name of macacamten is fV)-3-isopropyl-6-((l - phenylethyl)amino)pyrimidine-2,4( l//,3//)-dione. Mavacamten can be represented by the following chemical structure according to Formula (A)
Formula (A).
Mavacamten and its preparation are disclosed in WO 2014/205223 Al. In example 1 mavacamten is obtained as white solid after precipitation from ethyl acetate and further stirring in a solvent mixture of ethyl acetate/ «-hexane. The same process is disclosed in example 1 of WO 2019/028360 Al. Both documents are silent about the nature of the solid-state form obtained though.
Different solid-state forms of an active pharmaceutical ingredient (API) often possess different properties. Differences in physicochemical properties of solid-state forms can play a crucial role for the improvement of pharmaceutical compositions, for example, pharmaceutical
formulations with improved dissolution profile and bioavailability or with improved stability or shelf-life can become accessible due to an improved solid-state form of an active pharmaceutical ingredient. Also processing or handling of the active pharmaceutical ingredient during the formulation process may be improved. New solid-state forms of an active pharmaceutical ingredient can thus have desirable processing properties. They can be easier to handle, better suited for storage, and/or allow for better purification, compared to previously known solid-state forms.
For example, the sudden appearance or disappearance of a metastable polymorph can present a problem in pharmaceutical development. Similarly, serious pharmaceutical consequences may arise if transformation occurs in a dosage form, e.g. upon storage.
There is thus a need for the provision of solid-state forms of mavacamten having improved physicochemical properties. In particular, there is a strong need for the provision of a solid form of mavacamten which is stable and does not undergo phase transformation during pharmaceutical processing or storage. There is also a strong need for the provision of a pharmaceutical composition comprising a solid-state form of mavacamten, which is stable at the conditions typically encountered during pharmaceutical processing and storage.
SUMMARY OF THE INVENTION
The present invention provides anhydrous crystalline forms of mavacamten, hereinafter also designated as “Form I”, “Form II”, “Form III”, “Form IV”, “Form V” and “Form VI”.
The crystalline forms of the present invention possess one or more advantageous properties selected from the group consisting of chemical stability, physical stability, melting point, hygroscopicity, solubility, dissolution, morphology, crystallinity, flowability, bulk density, compactibility and wettability.
In particular, the crystalline forms of the present invention are stable against temperature stress e.g. they don’t show any thermal events during DSC up to a temperature of about 170°C.
In addition, mavacamten Form I of the present invention was found to be the most stable form at room temperature. The usage of a stable API form is of great importance since polymorphic conversions, which may occur during the manufacturing process and/or during storage of a drug substance or drug product containing the drug substance can be excluded when a stable form is
used. This ensures reliable bioavailability and therefore consistent efficacy and safety of the drug product containing the stable form throughout shelf-life.
Abbreviations
PXRD powder X-ray diffractogram
FTIR Fourier transform infrared
DSC differential scanning calorimetry
TGA thermogravimetric analysis
GMS gravimetric moisture sorption
NMP /V-methyl -2-pyrrol i done
HCM hypertrophic cardiomyopathy w-% weight percent
RH relative humidity
Definitions
In the context of the present invention the following definitions have the indicated meaning, unless explicitly stated otherwise:
As used herein, the term “measured at a temperature in the range of from 20 to 30°C” refers to a measurement under standard conditions. Typically, standard conditions mean a temperature in the range of from 20 to 30°C, i.e. at room temperature. Standard conditions can mean a temperature of about 22°C. Typically, standard conditions can additionally mean a measurement at 20-60% RH, preferably at 30-50% RH, more preferably at 40% RH.
As used herein the term “room temperature” refers to a temperature in the range of from 20 to 30°C.
The term “reflection” with regard to powder X-ray diffraction as used herein, means peaks in an X-ray diffractogram, which are caused at certain diffraction angles (Bragg angles) by constructive interference from X-rays scattered by parallel planes of atoms in solid material, which are distributed in an ordered and repetitive pattern in a long-range positional order. Such a solid material is classified as crystalline material, whereas amorphous material is defined as solid material, which lacks long-range order and only displays short-range order, thus resulting in broad scattering. According to literature, long-range order e.g. extends over approximately 100 to 1000 atoms, whereas short-range order is over a few atoms only (see “Fundamentals of
Powder Diffraction and Structural Characterization of Materials ” by Vitalij K. Pecharsky and Peter Y. Zavalij, Kluwer Academic Publishers, 2003, page 3).
The term “essentially the same” with reference to powder X-ray diffraction means that variabilities in reflection positions and relative intensities of the reflections are to be taken into account. For example, a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta. Thus, a reflection that usually appears at 10.1° 2-Theta for example can appear between 10.0° and 10.2° 2-Theta on most X-ray diffractometers under standard conditions. Furthermore, one skilled in the art will appreciate that relative reflection intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, particle size, sample preparation and other factors known to those skilled in the art and should be taken as qualitative measure only.
A crystalline form of mavacamten of the present invention may be referred to herein as being characterized by graphical data "as shown in" a figure. Such data include, for example, powder X-ray diffraction. The person skilled in the art understands that factors such as variations in instrument type, response and variations in sample directionality, sample concentration and sample purity may lead to small variations for such data when presented in graphical form, for example variations relating to the exact reflection positions and intensities. However, a comparison of the graphical data in the figures herein with the graphical data generated for another or an unknown solid form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
The term “solid-state form” as used herein refers to any crystalline and/or amorphous phase of a compound.
As used herein, the term “amorphous” refers to a solid-state form of a compound that is not crystalline. An amorphous compound possesses no long-range order and does not display a definitive X-ray diffraction pattern with reflections.
The terms “anhydrous form” or “anhydrate” as used herein refer to a crystalline solid where no water is cooperated in or accommodated by the crystal structure. Anhydrous forms may still contain residual water, which is not part of the crystal structure but may be adsorbed on the surface or absorbed in disordered regions of the crystal.
The term “non-solvated” as used herein, when talking about a crystalline solid indicates that no organic solvent is cooperated in or accommodated by the crystal structure. Non-solvated forms may still contain residual organic solvents, which are not part of the crystal structure but may be adsorbed on the surface or absorbed in disordered regions of the crystal.
A “predetermined amount” as used herein with regard to a crystalline form of mavacamten refers to the initial amount of the crystalline form used for the preparation of a pharmaceutical composition having a desired dosage strength of mavacamten.
The term “effective amount” as used herein with regard to a crystalline form of mavacamten encompasses an amount of the crystalline form which causes the desired therapeutic and/or prophylactic effect.
As used herein, the term “about” means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, typically within 10%, more typically within 5%, even more typically within 1% and most typically within 0.1% of the indicated value or range. Sometimes, such a range can lie within the experimental error, typical of standard methods used for the measurement and/or determination of a given value or range.
The term “pharmaceutically acceptable excipient” as used herein refers to substances, which do not show a significant pharmacological activity at the given dose and that are added to a pharmaceutical composition in addition to the active pharmaceutical ingredient. Excipients may take the function of vehicle, diluent, release agent, disintegrating agent, dissolution modifying agent, absorption enhancer, stabilizer or a manufacturing aid among others. Excipients may include fillers (diluents), binders, disintegrants, lubricants and glidants.
The terms “filler” or “diluent” as used herein refer to substances that are used to dilute the active pharmaceutical ingredient prior to delivery. Diluents and fillers can also serve as stabilizers.
As used herein the term “binder” refers to substances which bind the active pharmaceutical ingredient and pharmaceutically acceptable excipient together to maintain cohesive and discrete portions.
The terms “disintegrant” or “disintegrating agent” as used herein refers to substances which, upon addition to a solid pharmaceutical composition, facilitate its break-up or disintegration
after administration and permits the release of the active pharmaceutical ingredient as efficiently as possible to allow for its rapid dissolution.
The term “lubricant” as used herein refers to substances which are added to a powder blend to prevent the compacted powder mass from sticking to the equipment during tableting or encapsulation process. They aid the ejection of the tablet from the dies and can improve powder flow.
The term “glidant” as used herein refers to substances which are used for tablet and capsule formulations in order to improve flow properties during tablet compression and to produce an anti -caking effect.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1: illustrates a representative PXRD of mavacamten Form I according to the present invention. The x-axis shows the scattering angle in °2-Theta, the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
Figure 2: illustrates a representative PXRD of mavacamten Form II according to the present invention. The x-axis shows the scattering angle in °2-Theta, the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
Figure 3: illustrates a representative PXRD of mavacamten Form III according to the present invention. The x-axis shows the scattering angle in °2-Theta, the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
Figure 4: illustrates a representative PXRD of mavacamten Form IV according to the present invention. The x-axis shows the scattering angle in °2-Theta, the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
Figure 5: illustrates a representative PXRD of mavacamten Form V according to the present invention. The x-axis shows the scattering angle in °2-Theta, the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
Figure 6: illustrates a comparison of PXRDs of mavacamten Form I, Form II, Form III, Form IV and Form V (from top to bottom). The x-axis shows the scattering angle in °2-Theta. The PXRDs were shifted along the y-axis to separate the diffractograms for clarity.
Figure 7: illustrates a representative DSC curve of mavacamten Form I according to the present invention. The x-axis shows the temperature in degree Celsius (°C), the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
Figure 8: illustrates a representative DSC curve of mavacamten Form II according to the present invention. The x-axis shows the temperature in degree Celsius (°C), the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
Figure 9: illustrates a representative DSC curve of mavacamten Form III according to the present invention. The x-axis shows the temperature in degree Celsius (°C), the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
Figure 10: illustrates a representative DSC curve of mavacamten Form IV according to the present invention. The x-axis shows the temperature in degree Celsius (°C), the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
Figure 11: illustrates a representative DSC curve of mavacamten Form V according to the present invention. The x-axis shows the temperature in degree Celsius (°C), the y-axis shows the heat flow rate in milliwatt (mW) with endothermic peaks going up.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a crystalline form of mavacamten according to the chemical structure as depicted in Formula (A)
Formula (A), characterized in being anhydrous.
In particular the invention provides anhydrous crystalline forms of mavacamten, hereinafter also designated as “Form I”, “Form II”, “Form III”, “Form IV”, “Form V” and “Form VI”.
The crystalline forms of mavacamten of the present invention may be characterized by analytical methods well known in the field of the pharmaceutical industry for characterizing solids. Such methods comprise but are not limited to powder X-ray diffraction, single X-ray diffraction, FTIR spectroscopy, DSC, TGA and GMS. The crystalline forms of the present invention may be characterized by one of the aforementioned analytical methods or by combining two or more of them. In particular, the crystalline forms of mavacamten of the
present invention may be characterized by any one of the following embodiments or by combining two or more of the following embodiments.
Crystalline Form I of mavacamten
In one embodiment the invention relates to a crystalline form (Form I) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
(10.1 ± 0.1)°, (11.7 ± 0.1)° and (18.8 ± 0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)° and (18.8 ± 0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)°, (17.4 ± 0.1)° and (18.8 ± 0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)°, (15.8 ± 0.1)°, (17.4 ± 0.1)° and (18.8 ± 0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)°, (15.8 ± 0.1)°, (16.3 ± 0.1)°, (17.4 ± 0.1)° and (18.8 ±
0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)°, (15.8 ± 0.1)°, (16.3 ± 0.1)°, (17.4 ± 0.1)°, (18.8 ± 0.1)° and (22.4 ± 0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)°, (15.8 ± 0.1)°, (16.3 ± 0.1)°, (17.4 ± 0.1)°, (18.8 ± 0.1)°, (20.0 ± 0.1)° and (22.4 ± 0.1)°; or
(10.1 ± 0.1)°, (11.7 ± 0.1)°, (14.7 ± 0.1)°, (15.8 ± 0.1)°, (16.3 ± 0.1)°, (17.4 ± 0.1)°, (18.8 ± 0.1)°, (20.0 ± 0.1)°, (22.4 ± 0.1)° and (25.7 ± 0.1)°; when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
In a particular preferred embodiment, the invention relates to a crystalline form of mavacamten (Form I) as defined in any one of the above described embodiments characterized by having a PXRD comprising no reflections at or below (9.8 ± 0.1)° 2-Theta, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
In yet another embodiment, the present invention relates to a crystalline form of mavacamten (Form I) characterized by having a PXRD essentially the same as shown in Figure 1 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
In a further embodiment, the present invention relates to a crystalline form of mavacamten (Form I) characterized by exhibiting an orthorhombic unit cell having space group 2i2i2i. Preferably, the unit cell has the following parameters (at 25°C):
a = 9.45 Angstrom b = 12.07 Angstrom c = 2.66 Angstrom alpha = 90° beta = 90° gamma = 90°
In another embodiment, the present invention relates to a crystalline form (Form I) of mavacamten, characterized by having a melting point onset at a temperature of about 224.5°C, when measured with DSC at a heating rate of 10 K/min.
In one embodiment, the present invention relates to a crystalline form (Form I) of mavacamten characterized in being anhydrous.
In another embodiment, the present invention relates to a crystalline form (Form I) of mavacamten characterized in being non-solvated.
Crystalline Form II of mavacamten
In another embodiment the invention relates to a crystalline form (Form II) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
(8.5 ± 0.1)°, (11.9 ± 0.1)° and (13.4 ± 0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)° and (18.7 ± 0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)°, (15.8 ± 0.1)° and (18.7 ± 0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)°, (14.8 ± 0.1)°, (15.8 ± 0.1)° and (18.7 ± 0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)°, (14.8 ± 0.1)°, (15.8 ± 0.1)°, (18.7 ± 0.1)° and (23.8 ±
0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)°, (14.8 ± 0.1)°, (15.8 ± 0.1)°, (18.7 ± 0.1)°, (21.4 ± 0.1)° and (23.8 ± 0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)°, (14.8 ± 0.1)°, (15.8 ± 0.1)°, (18.7 ± 0.1)°, (20.1 ± 0.1)°, (21.4 ± 0.1)° and (23.8 ± 0.1)°; or
(8.5 ± 0.1)°, (11.9 ± 0.1)°, (13.4 ± 0.1)°, (14.8 ± 0.1)°, (15.8 ± 0.1)°, (16.6 ± 0.1)°, (18.7 ± 0.1)°, (20.1 ± 0.1)°, (21.4 ± 0.1)° and (23.8 ± 0.1)°; when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
In yet another embodiment, the present invention relates to a crystalline form of mavacamten (Form II) characterized by having a PXRD essentially the same as shown in Figure 2 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
In a further embodiment, the present invention relates to a crystalline form of mavacamten
(Form II) characterized by exhibiting an orthorhombic unit cell having space group P2\.
Preferably, the unit cell has the following parameters (at 25°C): a = 6.66 Angstrom b = 10.65 Angstrom c = 10.56 Angstrom alpha = 90° beta = 98.11° gamma = 90°
In another embodiment, the present invention relates to a crystalline form (Form II) of mavacamten, characterized by having a melting point onset at a temperature of about 238°C, when measured with DSC at a heating rate of 10 K/min.
In one embodiment, the present invention relates to a crystalline form (Form II) of mavacamten characterized in being anhydrous.
In another embodiment, the present invention relates to a crystalline form (Form II) of mavacamten characterized in being non-solvated.
Crystalline Form III of mavacamten
In another embodiment the invention relates to a crystalline form (Form III) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
(7.8 ± 0.1)°, (8.5 ± 0.1)° and (11.2 ± 0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)° and (17.0 ± 0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)°, (14.6 ± 0.1)° and (17.0 ± 0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)°, (14.6 ± 0.1)°, (15.6 ± 0.1)° and (17.0 ± 0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)°, (14.6 ± 0.1)°, (15.6 ± 0.1)°, (17.0 ± 0.1)° and (19.0 ±
0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)°, (14.6 ± 0.1)°, (15.6 ± 0.1)°, (17.0 ± 0.1)°, (19.0 ± 0.1)° and (21.5 ± 0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)°, (11.9 ± 0.1)°, (14.6 ± 0.1)°, (15.6 ± 0.1)°, (17.0 ± 0.1)°, (19.0 ± 0.1)° and (21.5 ± 0.1)°; or
(7.8 ± 0.1)°, (8.5 ± 0.1)°, (11.2 ± 0.1)°, (11.9 ± 0.1)°, (14.6 ± 0.1)°, (15.6 ± 0.1)°, (17.0 ± 0.1)°, (18.1 ± 0.1)°, (19.0 ± 0.1)° and (21.5 ± 0.1)°; when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
In yet another embodiment, the present invention relates to a crystalline form of mavacamten (Form III) characterized by having a PXRD essentially the same as shown in Figure 3 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
In a further embodiment, the present invention relates to a crystalline form of mavacamten
(Form III) characterized by exhibiting a monoclinic unit cell having space group 12 Preferably, the unit cell has the following parameters (at 25 °C): a = 14.94 Angstrom b = 6.65 Angstrom c = 15.89 Angstrom alpha = 90° beta = 94.81° gamma = 90°
In another embodiment, the present invention relates to a crystalline form (Form III) of mavacamten, characterized by having a melting point onset at a temperature of about 249.5°C, when measured with DSC at a heating rate of 10 K/min.
In one embodiment, the present invention relates to a crystalline form (Form III) of mavacamten characterized in being anhydrous.
In another embodiment, the present invention relates to a crystalline form (Form III) of mavacamten characterized in being non-solvated.
Crystalline Form IV of mavacamten
In another embodiment the invention relates to a crystalline form (Form IV) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
(7.3 ± 0.1)°, (11.4 ± 0.1)° and (18.2 ± 0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (13.0 ± 0.1)° and (18.2 ± 0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (12.0 ± 0.1)°, (13.0 ± 0.1)° and (18.2 ± 0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (12.0 ± 0.1)°, (13.0 ± 0.1)°, (14.6 ± 0.1)° and (18.2 ± 0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (12.0 ± 0.1)°, (13.0 ± 0.1)°, (13.5 ± 0.1)°, (14.6 ± 0.1)° and (18.2 ±
0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (12.0 ± 0.1)°, (13.0 ± 0.1)°, (13.5 ± 0.1)°, (14.6 ± 0.1)°, (15.8 ± 0.1)° and (18.2 ± 0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (12.0 ± 0.1)°, (13.0 ± 0.1)°, (13.5 ± 0.1)°, (14.6 ± 0.1)°, (15.8 ± 0.1)°, (18.2 ± 0.1)° and (23.2 ± 0.1)°; or
(7.3 ± 0.1)°, (11.4 ± 0.1)°, (12.0 ± 0.1)°, (13.0 ± 0.1)°, (13.5 ± 0.1)°, (14.6 ± 0.1)°, (15.8 ± 0.1)°, (18.2 ± 0.1)°, (19.3 ± 0.1)° and (23.2 ± 0.1)°; when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
In yet another embodiment, the present invention relates to a crystalline form of mavacamten (Form IV) characterized by having a PXRD essentially the same as shown in Figure 4 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
In a further embodiment, the present invention relates to a crystalline form of mavacamten
(Form IV) characterized by exhibiting an orthorhombic unit cell having space group 2i2i2i.
Preferably, the unit cell has the following parameters (at 25°C): a = 9.85 Angstrom b = 12.60 Angstrom c = 24.24 Angstrom alpha = 90° beta = 90° gamma = 90°
In another embodiment, the present invention relates to a crystalline form (Form IV) of mavacamten, characterized by having a melting point onset at a temperature of about 236°C, when measured with DSC at a heating rate of 10 K/min.
In one embodiment, the present invention relates to a crystalline form (Form IV) of mavacamten characterized in being anhydrous.
In another embodiment, the present invention relates to a crystalline form (Form IV) of mavacamten characterized in being non-solvated.
Crystalline Form V of mavacamten
In another embodiment the invention relates to a crystalline form (Form V) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
(9.3 ± 0.1)°, (11.7 ± 0.1)° and (13.3 ± 0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)° and (13.9 ± 0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)°, (13.9 ± 0.1)° and (18.7 ± 0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)°, (13.9 ± 0.1)°, (18.7 ± 0.1)° and (20.8 ± 0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)°, (13.9 ± 0.1)°, (17.7 ± 0.1)°, (18.7 ± 0.1)° and (20.8 ±
0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)°, (13.9 ± 0.1)°, (15.7 ± 0.1)°, (17.7 ± 0.1)°, (18.7 ± 0.1)° and (20.8 ± 0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)°, (13.9 ± 0.1)°, (15.7 ± 0.1)°, (16.3 ± 0.1)°, (17.7 ± 0.1)°, (18.7 ± 0.1)° and (20.8 ± 0.1)°; or
(9.3 ± 0.1)°, (11.7 ± 0.1)°, (13.3 ± 0.1)°, (13.9 ± 0.1)°, (15.7 ± 0.1)°, (16.3 ± 0.1)°, (16.8 ± 0.1)°, (17.7 ± 0.1)°, (18.7 ± 0.1)° and (20.8 ± 0.1)°; when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
In yet another embodiment, the present invention relates to a crystalline form of mavacamten (Form V) characterized by having a PXRD essentially the same as shown in Figure 5 of the present invention, when measured at a temperature in the range of from 20 to 30°C with Cu- Kalphai,2 radiation having a wavelength of 0.15419 nm.
In a further embodiment, the present invention relates to a crystalline form of mavacamten (Form V) characterized by exhibiting an orthorhombic unit cell having space group 2i2i2. Preferably, the unit cell has the following parameters (at 25°C):
a = 10.52 Angstrom b = 21.79 Angstrom c = 6.66 Angstrom alpha = 90° beta = 90° gamma = 90°
In another embodiment, the present invention relates to a crystalline form (Form V) of mavacamten, characterized by having a melting point onset at a temperature of about 240°C, when measured with DSC at a heating rate of 10 K/min.
In one embodiment, the present invention relates to a crystalline form (Form V) of mavacamten characterized in being anhydrous.
In another embodiment, the present invention relates to a crystalline form (Form V) of mavacamten characterized in being non-solvated.
Crystalline Form VI of mavacamten
In another embodiment the invention relates to a crystalline form (Form VI) of mavacamten characterized by having a PXRD comprising reflections at 2-Theta angles of:
(5.9 ± 0.1)°, (9.7 ± 0.1)° and (17.8 ± 0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)° and (17.8 ± 0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)°, (11.8 ± 0.1)° and (17.8 ± 0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)°, (11.8 ± 0.1)°, (14.1 ± 0.1)° and (17.8 ± 0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)°, (11.8 ± 0.1)°, (14.1 ± 0.1)°, (17.8 ± 0.1)° and (18.5 ±
0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)°, (11.8 ± 0.1)°, (14.1 ± 0.1)°, (17.8 ± 0.1)°, (18.3 ± 0.1)° and (18.5 ± 0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)°, (11.8 ± 0.1)°, (14.1 ± 0.1)°, (17.8 ± 0.1)°, (18.3 ± 0.1)°, (18.5 ± 0.1)° and (18.8 ± 0.1)°; or
(5.9 ± 0.1)°, (8.3 ± 0.1)°, (9.7 ± 0.1)°, (11.8 ± 0.1)°, (13.9 ± 0.1)°, (14.1 ± 0.1)°, (17.8 ± 0.1)°, (18.3 ± 0.1)°, (18.5 ± 0.1)° and (18.8 ± 0.1)°; when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphal,2 radiation having a wavelength of 0.15419 nm.
In one embodiment, the present invention relates to a crystalline form (Form VI) of mavacamten characterized in being anhydrous.
In another embodiment, the present invention relates to a crystalline form (Form VI) of mavacamten characterized in being non-solvated.
Pharmaceutical compositions and medical use
In a further aspect, the present invention relates to the use of crystalline mavacamten ( e.g . Form
I, II, III, IV, V or VI as defined herein) of the present invention as defined in any one of the above described aspects and their corresponding embodiments for the preparation of a pharmaceutical composition.
Furthermore, the present invention relates to a pharmaceutical composition comprising crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) of the present invention as defined in any one of the above described aspects and their corresponding embodiments, preferably in an effective and/or predetermined amount, and at least one pharmaceutically acceptable excipient.
Preferably, the effective and/or predetermined amount of crystalline mavacamten (e.g. Form I,
II, III, IV, V or VI as defined herein) of the present invention is in the range of from about 1 to 50 mg, preferably of from about 2 to 30 mg and most preferably of from about 2.5 to 15 mg calculated as mavacamten (water free). For example, the effective and/or predetermined amount is selected from the group consisting of 1 mg, 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg and 50 mg calculated as mavacamten (water free). Preferably, the effective and/or predetermined amount is selected from the group consisting of 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg calculated as mavacamten (water free).
The at least one pharmaceutically acceptable excipient, which is comprised in the pharmaceutical composition of the present invention, is preferably selected from the group consisting of fillers, disintegrants, binders, lubricants, glidants and combinations thereof. Preferably, the at least one pharmaceutically acceptable excipient, which is comprised in the pharmaceutical composition of the present invention is selected from the group consisting of fillers, glidants and combinations thereof.
In one embodiment, the filler is selected from the group consisting of dibasic calcium phosphate, kaolin, lactose, dextrose, magnesium carbonate, sucrose, mannitol, glucose or other monosaccharides, dextrin or other polysaccharides, microcrystalline cellulose, powdered cellulose, cellulose derivatives, precipitated calcium carbonate, calcium sulfate, sorbitol, inositol and starch, and combinations thereof.
In one embodiment, the glidant is selected from the group consisting of coloidal silica, colloidal silicon dioxide, fumed silica, silicon dioxide, com starch, talc, calcium silicate, magnesium silicate, tribasic calcium phosphate, silicon hydrogel, and combinations thereof.
Preferably, the pharmaceutical composition of the present invention as defined in any one of the above described embodiments is an oral solid dosage form, more preferably a tablet or a capsule. In a particular preferred embodiment, the pharmaceutical composition of the present invention as described above is a capsule, preferably a hard gelatin capsule.
The pharmaceutical compositions of the present invention as defined in any one of the above described embodiments may be produced by standard manufacturing processes, which are well- known to the skilled person e.g. selected from the group consisting of micronization, blending, milling, granulation (wet or dry granulation), capsule filling, tabletting, film-coating and any combinations thereof.
In a further aspect, the present invention relates to crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) or a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments for use as a medicament.
In still a further aspect, the present invention relates to crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) or a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments for use in the treatment of cardiac disorder.
In another aspect, the present invention relates to a method of treating a cardiac disorder said method comprising administering an effective amount of crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) or a pharmaceutical composition comprising a crystalline form of mavacamten as defined in any one of the above described aspects and their corresponding embodiments to a patient in need of such a treatment.
In a preferred embodiment, the cardiac disorder is selected from the group consisting of hypertrophic cardiomyopathy (HCM), such as obstructive HCM and non-obstructive HCM, and precision diastolic disease. In a particular preferred embodiment, the cardiac disorder is ostructive HCM.
Use as intermediates for salt preparation
In another aspect the invention relates to crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) for use in the preparation of a pharmaceutically acceptable salt of mavacamten.
In one embodiment the pharmaceutically acceptable salt is an acid addition salt or a base addition salt, preferably an acid addition salt. Pharmaceutically acceptable salts may be derived by reacting crystalline mavacamten (e.g. Form I, II, III, IV, V or VI as defined herein) with an acid or a base in a suitable solvent or solvent mixture. The acid may be selected from the group consisting of acetic acid, adipic acid, alginic acid, aminosalicylic acid, /.-ascorpic acid, L- aspartic acid, aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphor-10-sulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, galactaric acid, //-glucaric acid, //-gluconic acid, //-glucuronic acid, /.-gluta ic acid, glutaric acid, hippuric acid, hydrochloric acid, hydrobromic acid, lactic acid, lactobionic acid, lauric acid, malic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, naphtalene-l,5-disulfonic acid, naphtelene-2- sulfonic acid, nitric acid, oxalic acid, pamoic acid, phosphoric acid, salicylic acid, stearic acid, succinic acid, sulfonic acid, tartaric acid and /i-toluene sulfonic acid. The base may be selected from the group consisting of aluminum, ammonia, /.-arginine, benethamine, benzathine, tert- butylamine, calcium hydroxide, chloroprocaine, choline hydroxide, diethanolamine, diethylamine, ethanolamine, ethylenediamine, lithium, /.-lysine, magnesium hydroxide, meglumine, piperazine, potassium hydroxide, procaine, sodium hydroxide, tromethamine and zinc hydroxide.
EXAMPLES
The following non-limiting examples are illustrative for the disclosure and are not to be construed as to be in any way limiting for the scope of the invention. The mavacamten starting material was obtained by following the procedure disclosed in example 1 of WO 2014/205223 Al.
Example 1: Preparation of mavacamten Form I
Mavacamten (45 mg) was dissolved in ethanol (1.8 mL) upon heating. The resulting clear solution was filtrated and allowed to naturally cool to room temperature, whereat crystals formed within 24 hours. Subsequently, the mixture was cooled to -20°C for about 16 hours before the crystals were collected by filtration and air-dried to obtain crystalline Form I of mavacamten.
Example 2: Preparation of mavacamten Form II
Mavacamten (15 mg) was dissolved in methanol (2.3 mL) at room temperature. The obtained clear solution was filtrated and transferred to a watch glass for solvent evaporation at room temperature to obtain crystalline Form II of mavacamten
Example 3: Preparation of mavacamten Form III
Mavacamten (Form I, Form II, Form IV or Form V prepared according to the procedures disclosed herein) was annealed at 240°C for 5 minutes and at 210°C for 10 minutes. The sample was then cooled to room temperature to obtain crystalline Form III of mavacamten.
Example 4: Preparation of mavacamten Form IV
Mavacamten (130 mg) was dissolved in isopropanol (20 mL) upon heating to reflux temperature. The resulting clear solution was filtrated and the solvent removed on a rotavapor (40°C, 50-100 mbar) under reduced pressure to obtain crystalline Form IV of mavacamten.
Example 5: Preparation of mavacamten Form V
Mavacamten (80 mg) was dissolved in chloroform (12 mL) upon heating. The resulting clear solution was filtrated and the solvent removed on a rotavapor (40°C, 250-350 mbar) under reduced pressure to obtain crystalline Form V of mavacamten.
Example 6: Preparation of mavacamten Form VI
Mavacamten (15 mg) was dissolved in pyridine (1 mL). The resulting clear solution was filtered and transferred to a watch glass for solvent evaporation at room temperature. Within one day needle shaped crystals of form VI were obtained.
Example 7: Preparation of mavacamten pyridine /lew/solvate
Mavacamten (92 mg) was dissolved in pyridine (2.7 mL) upon heating. The resulting clear solution was filtrated and the solvent removed on a rotavapor (40°C, 10-100 mbar) to obtain the mavacamten pyridine /lew/solvate.
Example 8: Preparation of mavacamten chloroform /wi/zosolvate
Mavacamten (85 mg) was dissolved in chloroform (11 mL) upon heating. The resulting clear solution was filtrated and the solvent removed on a rotavapor (25 °C, 100 mbar) to obtain the mavacamten chloroform /wwosolvate.
Mavacamten (20 mg) was dissolved in A -m ethyl -2-pyrrol i done (1 mL). The resulting clear solution was filtrated and transferred to a watch glass for solvent evaporation at room temperature. After approximately 2 weeks needle shaped NMP solvate crystals and blocks (Form I) were obtained.
Example 10: Powder X-ray diffraction
The powder X-ray diffraction patterns were recorded (at 25°C) with a X’Pert PRO diffractometer (PANalytical, Almelo, The Netherlands), equipped with a Theta/Theta coupled goniometer in transmission geometry, programmable XYZ stage with well plate holder, Cu- Kalphai,2 radiation source with a focussing mirror, a 0.5° divergence slit, a 0.02° sober slit collimator and a 1° anti -scattering slit on the incident beam side, a 2 mm anti -scattering slit, a 0.04° sober slit collimator, a Ni-filter, and a solid state PIXcel detector on the diffracted beam side. The patterns were recorded at a tube voltage of 40 kV, tube current of 40 mA, applying a step-size of 0.007° 2-Theta with 400 s per step in the angular range of 2° to 70° 2-Theta.
A representative diffractogram of mavacamten Form I is displayed in Figure 1 hereinafter. The corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 1 below.
Table 1: Reflection positions of crystalline Form I of mavacamten in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
A representative diffractogram of mavacamten Form II is displayed in Figure 2 hereinafter. The corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 2 below.
Table 2: Reflection positions of crystalline Form II of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
A representative diffractogram of mavacamten Form III is displayed in Figure 3 hereinafter. The corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 3 below.
Table 3: Reflection positions of crystalline Form III of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
A representative diffractogram of mavacamten Form IV is displayed in Figure 4 hereinafter. The corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 4 below.
Table 4: Reflection positions of crystalline Form IV of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
A representative diffractogram of mavacamten Form V is displayed in Figure 5 hereinafter. The corresponding reflection list in the range of from 2 to 30° 2-Theta is provided in Table 5 below.
Table 5: Reflection positions of crystalline Form V of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta. The reflection list of mavacamten Form VI in the range of from 2 to 30° 2-Theta is provided in
Table 6: Reflection positions of crystalline form VI of mavacamten in the range of from 2 to 30° 2- Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
The reflection list of mavacamten pyridine hemi solvate in the range of from 2 to 30° 2-Theta is provided in Table 7 below.
Table 7: Reflection positions of crystalline mavacamten pyridine hera/solvate in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
The reflection list of mavacamten chloroform /ww solvate in the range of from 2 to 30° 2- Theta is provided in Table 8 below.
Table 8: Reflection positions of crystalline mavacamten chloroform monosolvate in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
The reflection list of mavacamten NMP hemi solvate in the range of from 2 to 30° 2-Theta is provided in Table 9 below.
Table 9: Reflection positions of crystalline mavacamten NMP hemisolvatc in the range of from 2 to 30° 2-Theta; a typical precision of the 2-Theta values is in the range of ± 0.1° 2-Theta.
Example 11: Crystal structures
Mavacamten Forms I to V were indexed and the space groups were determined based on a statistical assessment of systematic absences using DicvoKM1 as implemented in HighScore Plus 3.0.5 (PANalytical, Almelo, The Netherlands). Pawley fits and Rietveld refinements were performed with Topas v.4.1 (Bruker AXS Inc., Madison, Wisconsin, USA).
Table 10: Crystallographic information for mavacamten forms I to V
Example 12: Differential Scanning Calorimetry
Differential Scanning Calorimetry (DSC) thermograms were recorded on a DSC 7 (Perkin- Elmer, Norwalk, Connecticut, USA) controlled by the Pyris software. Using a UM3 ultra microbalance (Mettler, Greifensee, CH), samples of approximately 2 - 3 mg were weighed into perforated aluminum pans, then heated at a rate of 10 K/min with dry nitrogen as the purge gas (purge: 20 mL/min). The instrument was calibrated for temperature with pure benzophenone (mp 48.0°C) and caffeine (236.2°C), and the energy calibration was performed with indium (mp 156.6°C, heat of fusion 28.45 J/g).
Representative DSC curves of mavacamten Forms I to V are displayed in Figures 7 to 11 hereinafter and the results are sumarized in Table 11 below.
Table 11: Melting points of various anhydrous mavacamten forms
Claims
Formula (A), characterized in being anhydrous.
2) The crystalline form of claim 1 in crystalline Form I, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (10.1 ± 0.1)°, (11.7 ± 0.1)° and (18.8 ± 0.1)° and comprising no reflection at or below (9.8 ± 0.1)° 2-Theta, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
3) The crystalline form of claim 1 in crystalline Form II, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (8.5 ± 0.1)°, (11.9 ± 0.1)° and (13.4 ± 0.1)°, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
4) The crystalline form of claim 1 in crystalline Form III, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (7.8 ± 0.1)°, (8.5 ± 0.1)° and (11.2 ± 0.1)°, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
5) The crystalline form of claim 1 in crystalline Form IV, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (7.3 ± 0.1)°, (11.4 ± 0.1)° and (18.2 ± 0.1)°, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
6) The crystalline form of claim 1 in crystalline Form V, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (9.3 ± 0.1)°, (11.7 ± 0.1)° and (13.3 ± 0.1)°, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm.
7) The crystalline form of claim 1 in crystalline Form VI, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (5.9 ± 0.1)°, (9.7 ± 0.1)° and (17.8 ± 0.1)°, when measured at a temperature in the range of from 20 to 30°C with Cu-Kalphai,2 radiation having a wavelength of 0.15419 nm. 8) The crystalline form according to any one of the preceding claims characterized in being non-solvated.
9) Use of the crystalline form as defined in any one of the preceding claims for the preparation of a pharmaceutical composition.
10) A pharmaceutical composition comprising a predetermined and/or effective amount of the crystalline form as defined in any one of claims 1 to 8 and at least one pharmaceutically acceptable excipient.
11) The pharmaceutical composition according to claim 10 which is an oral solid dosage form.
12) The pharmaceutical composition according to claim 11 which is a tablet or a capsule. 13) The crystalline form as defined in any one of claims 1 to 8 or the pharmaceutical composition as defined in any one of claims 10 to 12 for use as a medicament.
14) The crystalline form as defined in any one of claims 1 to 8 or the pharmaceutical composition as defined in any one of claims 10 to 12 for use in the treatment of a cardiovascular disease. 15) The use according to claim 14, wherein the cardiovascular disease is hypertrophic cardiomyopathy (HCM).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21162206 | 2021-03-12 | ||
EP21162206.3 | 2021-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022189599A1 true WO2022189599A1 (en) | 2022-09-15 |
Family
ID=74873521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/056267 WO2022189599A1 (en) | 2021-03-12 | 2022-03-10 | Crystalline forms of mavacamten for the treatment of hcm |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022189599A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112939876A (en) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Crystal form I of Mavacamten and preparation method thereof |
WO2023199258A1 (en) * | 2022-04-13 | 2023-10-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of mavacamten and process for preparation thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014205223A1 (en) | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Pyrimidinedione compounds against cardiac conditions |
WO2019028360A1 (en) | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
WO2021092598A1 (en) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
CN112939876A (en) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Crystal form I of Mavacamten and preparation method thereof |
WO2021154904A1 (en) * | 2020-01-28 | 2021-08-05 | Teva Pharmaceuticals International Gmbh | Solid state forms of mavacamten and process for preparation thereof |
-
2022
- 2022-03-10 WO PCT/EP2022/056267 patent/WO2022189599A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014205223A1 (en) | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Pyrimidinedione compounds against cardiac conditions |
WO2019028360A1 (en) | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
WO2021092598A1 (en) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
WO2021154904A1 (en) * | 2020-01-28 | 2021-08-05 | Teva Pharmaceuticals International Gmbh | Solid state forms of mavacamten and process for preparation thereof |
CN112939876A (en) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Crystal form I of Mavacamten and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112939876A (en) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Crystal form I of Mavacamten and preparation method thereof |
WO2023199258A1 (en) * | 2022-04-13 | 2023-10-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of mavacamten and process for preparation thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022189599A1 (en) | Crystalline forms of mavacamten for the treatment of hcm | |
US20220267299A1 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
US11028100B2 (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
CA3074529C (en) | Co-crystal of roxadustat with l-proline and uses thereof | |
US11603363B2 (en) | Crystalline form of LNP023 | |
EP3808742A1 (en) | Polymorph of selinexor | |
ES2949662T3 (en) | Pharmaceutical compound, salts thereof, formulations thereof and methods of manufacture and use thereof | |
US20210206770A1 (en) | Co-Crystal of an Orally Available Janus Kinase Inhibitor | |
JP2018111718A (en) | SOLID SALT OF α-6-MPEG6-O-HYDROXYCODONE AS OPIOID AGONISTS AND USES THEREOF | |
JP2009503065A (en) | Novel salt II | |
JP2020500936A (en) | Compositions and methods relating to pyridinoylpiperidine 5-HT1F agonists | |
WO2022269008A1 (en) | Crystalline form of sotorasib | |
WO2022069357A1 (en) | Crystalline form of selpercatinib | |
WO2021259732A1 (en) | Multi-component compounds comprising zanubrutinib and a benzoic acid derivative | |
TW202241425A (en) | Process for manufacturing a diphenylpyrazine derivative | |
US11236066B2 (en) | Crystalline forms of niraparib tosylate | |
EP3887356B1 (en) | Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor | |
EP3587421A1 (en) | Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide | |
JP2021501771A (en) | Crystalline salt of tricyclic poly (ADP-ribose) polymerase inhibitor | |
JP2009503066A (en) | Novel salt III | |
JP5265876B2 (en) | Andlast's new and stable crystal structure | |
WO2021156140A1 (en) | Polymorph of rucaparib mesylate | |
EP4227305A1 (en) | Crystalline form of sotorasib | |
EP3517529B1 (en) | Salt of quinazoline derivative, preparation method therefor and application thereof | |
WO2020161284A1 (en) | Crystalline form of iclaprim mesylate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22711994 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22711994 Country of ref document: EP Kind code of ref document: A1 |